NEW YORK — With the recent publication of two peer-reviewed papers, Alzheimer's testing firm C₂N Diagnostics continues to build the case for its blood-based test.
360Dx: C₂N Building Case for Alzheimer's Dx as Aducanumab Approval Promises to Impact Testing Space
Previous
Previous
Evaluate Vantage: Aduhelm approval amplifies amyloid assays
Next
Next